Figure 2.
EV release inhibitors GW4869, manumycin A, FTY720, and JTE-013 induced accumulation of intracellular miRNAs in MM-BMSCs. (A) Western blot analysis of EV markers CD63, CD81, and TSG101 verified that the inhibitors reduced EV release. (B) TaqMan low-density miRNA array analysis of cellular miRNA expression (miR-10a, miR-346, and miR-135b) in normal-BMSCs (n = 2) and MM-BMSCs (n = 6) treated with EV release inhibitors. *P < .01 vs control without EV release inhibitors. (C) Immunofluorescence staining of CD63 (green) in normal-BMSCs and MM-BMSCs to visualize the accumulation of EVs after treatment with FTY720. KDEL (red) and 4′,6-diamidino-2-phenylindole (DAPI; blue) were used as cytoplasmic and nuclear counterstains, respectively. Scale bars, 50 nm.

EV release inhibitors GW4869, manumycin A, FTY720, and JTE-013 induced accumulation of intracellular miRNAs in MM-BMSCs. (A) Western blot analysis of EV markers CD63, CD81, and TSG101 verified that the inhibitors reduced EV release. (B) TaqMan low-density miRNA array analysis of cellular miRNA expression (miR-10a, miR-346, and miR-135b) in normal-BMSCs (n = 2) and MM-BMSCs (n = 6) treated with EV release inhibitors. *P < .01 vs control without EV release inhibitors. (C) Immunofluorescence staining of CD63 (green) in normal-BMSCs and MM-BMSCs to visualize the accumulation of EVs after treatment with FTY720. KDEL (red) and 4′,6-diamidino-2-phenylindole (DAPI; blue) were used as cytoplasmic and nuclear counterstains, respectively. Scale bars, 50 nm.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal